BSEConcord Drugs LtdMinimalNeutral
Announced Fri, 10 Apr · 18:10 IST

<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+8.5%1-day move
₹74.18
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+8.5+11.9+15.9+13.9+18.0+15.7+11.9+9.2+10.4-3.1
Up moveDown movePending
AI summary

Concord Drugs Ltd has informed the BSE that it does not qualify as a 'Large Corporate' under SEBI's framework as of March 31, 2026. This is based on the criteria mentioned in SEBI's circulars on debt securities fund raising by large corporates. As a result, the company is not required to file the Annual Disclosure (Annexure B2) for the financial year 2025-26. The communication was signed by Whole Time Director S Manoj Kumar Reddy. This is a routine, compliance-related confirmation rather than a business or financial event.

Likely market impact

This is a neutral, procedural filing with no material impact on shareholders or the stock price. It simply confirms that the company is below the size threshold that would trigger SEBI's Large Corporate obligations, such as mandatory debt issuance requirements.